Lack of association between CTLA-4 +49A/G and -318c/t polymorphisms and behçet's disease risk: A meta-analysis

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Zhang, Yu Jing ^a   Xu, Wang Dong ^a   Duan, Zhen Hua ^a   Liu, Shan Shan ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Beh et's syndrome; CTLA 4; Meta analysis; Polymorphism

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CTLA4 PROTEIN, HUMAN;

ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; CTLA 4 GENE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ETHNIC GROUP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TURKISH; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; META ANALYSIS; PHENOTYPE; REVIEW; RISK;

BEHCET SYNDROME; CTLA-4 ANTIGEN; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84873271051     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. SAKANE T, TAKENO M, SUZUKI N, INABA G, Behçet's disease. N Engl J Med 1999; 341: 1284-91.
2. SEYAHI E, YURDAKUL S, Behçet's Syndrome and Thrombosis. Mediterr J Hematol Infect Dis 2011; 3: e2011026.
3. ARAYSSI T, HAMDAN A, New insights into the pathogenesis and therapy of Behçet's disease. Curr Opin Pharmacol 2004; 4: 183-8.
4. DE MENTHON M, LAVALLEY MP, MALDINI C, GUILLEVIN L, MAHR A, HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61: 1287-96.
5. GÜL A, HAJEER AH, WORTHINGTON J, BARRETT JH, OLLIER WE, SILMAN AJ, Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001; 44: 239-40.
6. LEE KM, CHUANG E, GRIFFIN M et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282: 2263-6.
7. DÜZGÜN N, DUMAN T, KESKIN O, MORRIS Y, TUTKAK H, Cytotoxic T lymphocyte antigen-4 (CTLA-4) polymorphism in patients with Behçet's disease. Clin Exp Rheumatol 2010; 28: S100.
8. DU L, YANG P, HOU S, ZHOU H, KIJLSTRA A, No association of CTLA-4 polymorphisms with susceptibility to Behçet disease. Br J Ophthalmol 2009; 93: 1378-81.
9. PARK KS, BAEK JA, DO JE, BANG D, LEE ES, CTLA4 gene polymorphisms and soluble CTLA4 protein in Behçet's disease. Tissue Antigens 2009; 74: 222-7.
10. BEN DHIFALLAH I, CHELBI H, BRAHAM A, HAMZAOUI K, HOUMAN MH, CTLA-4 +49A/G polymorphism is associated with Behçet's disease in a Tunisian population. Tissue Antigens 2009; 73: 213-7.
11. BYE L, MODI N, STANFORD MR et al. CTLA-4 polymorphisms are not associated with ocular inflammatory disease. Tissue Antigens 2008; 72: 49-53.
12. GUNESACAR R, ERKEN E, BOZKURT B et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behçet's disease. Int J Immunogenet 2007; 34: 45-9.
13. SALLAKCI N, BACANLI A, COSKUN M, YAVUZER U, ALPSOY E, YEGIN O, CTLA-4 gene 49A/G polymorphism in Turkish patients with Behçet's disease. Clin Exp Dermatol 2005; 30: 546-50.
14. TOUMA Z, HAMDAN A, SHAMSEDDEEN W et al. CTLA-4 gene variants are not associated with Behçet's disease or its clinical manifestations. Clin Exp Rheumatol 2008; 26: S132.
15. REMMERS EF, COSAN F, KIRINO Y et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42: 698-702.
16. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335: 1078-80.
17. YURDAKUL S, YAZICI H, Behçet's syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793-809.
18. PINETON DE CHAMBRUN M, WECHSLER B, GERI G, CACOUB P, SAADOUN D, New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012; 11: 687-98.
19. ZHAO C, YANG P, HE H et al. S-antigen specific T helper type 1 response is present in Behçet's disease. Mol Vis 2008; 14: 1456-64.
20. BEN AHMED M, HOUMAN H, MILED M, DELLAGI K, LOUZIR H, Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum 2004; 50: 2291-5.
21. TIVOL EA, BORRIELLO F, SCHWEITZER AN, LYNCH WP, BLUESTONE JA, SHARPE AH, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-7.
22. CHEN ZT, XIA B, JIANG T, ZHOU F, ZOU KF, GE LQ, CTLA-4 gene polymorphism regulates CTLA-4 mRNA stability and protein level in patients with ulcerative colitis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010; 27: 603-9.
23. DAROSZEWSKI J, PAWLAK E, KARABON L et al. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur J Endocrinol 2009; 161: 787-93.
24. SIM JH, PARK MJ, PARK S, LEE ES, Altered expression of costimulatory molecules in Behçet's disease according to clinical activity. Br J Dermatol 2011; 164: 1285-91.
25. + regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol 2006; 24: S71-8.